Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2011

View Archived Issues

MRI-detected changes in brain gray matter can predict chronic low back pain

Astellas Pharma describes new orally available prostanoid DP2 receptor antagonists

Progenra's ubiquitin carboxyl-terminal hydrolase inhibitors show preclinical antitumor activity

Roche presents selective small-molecule farnesoid X receptor agonists

Phrixus Pharma receives NIH awards to study Carmeseal in DMD and heart failure

Sangamo and CHDI Foundation join to develop ZFP therapy for Huntington's disease

New farnesoid X receptor agonist Px-20606 prevents nonalcoholic steatohepatitis in an animal model

Millenium Pharma and Sunesis Pharma enter agreement for kinase inhibitors in oncology

AXL-1717 exhibits safety/tolerability in subjects with advanced tumors in phase I/II trial

Multiple studies of hepatitis C treatment telaprevir presented at International Liver Congress

New NHE-1 inhibitors identified for prevention of ischemic damage

PfCDK1 inhibitors show promise as new antimalarials in preclinical assessment

Achaogen presents new fluoroquinolones with antibacterial activity

AstraZeneca synthesizes novel GPR119 receptor agonists

Novel radiolabeled deuterated CLR-1404 derivatives described by Cellectar

Novartis patents new Toll-like receptor 7 agonists as vaccine adjuvants

New HSP 90 inhibitors for cancer presented by sanofi-aventis

PRISM and Eisai collaborate on PRI-724

REGN-727 dose-dependently reduces LDL-cholesterol in phase I trial

LabCorp to acquire Orchid Cellmark

Valeant Pharma's unsolicited proposal to purchase Cephalon rejected

Optimer and Cubist Pharma to copromote Dificid for Clostridium difficile infection

PharmaGap prepares to advance GAP-107B8 to clinical trials in cancer

FDA approves Horizant for restless legs syndrome

Antitumor activity of TAK-441 involves inhibition of zinc finger protein GLI1 expression

Novartis to sell global rights for Elidel to Meda

FDA approves vandetanib for medullary thyroid cancer

SuperGen and Astex Therapeutics enter merger agreement

OBT to use BioWa's Potelligent technology for cancer programs

DSP and BBI sign option license agreement for anticancer drug

Phase II results reported on T-DM1 in HER2-positive metastatic breast cancer

Novel fluoroquinolone antibacterial agents claimed

Novartis discloses new inhibitors of cyclin-dependent kinase 9

New antibiotics synthesized at Piramal Life Sciences

Chifcon Medicine R&D describes natural antitumor agents coupled to NO donors

Biotie begins phase IIb trial of SYN-115 in Parkinson's disease

Dipexium presents pipeline update and milestones for 2011

First phase I trial begins for IMC-3C5 in advanced solid tumors

Bradmer Pharma ends Neuradiab license agreement for glioblastoma multiforme

Medicago enters research collaboration for noninfluenza vaccine candidate

Japanese launch of Edirol for osteoporosis expected this month

Alexion Pharmaceuticals files for FDA and EMA approval of Soliris in aHUS

Marina Biotech advances phase Ib/IIa trial of CEQ-508 in FAP

Lpath begins enrollment in phase Ia/IIb trial of ocular agent iSONEP

Zacharon and Pfizer join to develop drugs for orphan diseases

Shionogi's Cuvposa available in U.S. for chronic severe drooling

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.